A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2017
At a glance
- Drugs DS 3032b (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 10 Jun 2017 Biomarkers information updated
- 30 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Jul 2018.
- 30 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Apr 2018.